Education
About Us
Working with TipRanks
Follow Us
Rallybio (RLYB)
NASDAQ:RLYB
RLYB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $2.00
Previous CloseN/A
Volume36.64K
Average Volume (3M)153.27K
Market Cap
$13.19M
Enterprise Value-$22.48M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.58
Next Earnings
May 13, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding41,612,038
10 Day Avg. Volume71,523
30 Day Avg. Volume153,271
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-35.35
Enterprise Value/Ebitda0.37
Forecast
1Y Price Target
$7.00Price Target Upside2087.50% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Cash PositionRallybio ended with $66M in cash, which provides runway into the second half of 2026.
Investor InterestPhase 1 data for differentiated C5 inhibitor RLYB116 could draw investor interest back to RLYB.
Pipeline DevelopmentRallybio will focus its resources on advancing other pipeline programs, notably RLYB116, an inhibitor of complement component 5 with potential applications in treating complement-related diseases.
Bears Say
Clinical Data ChallengesRLYB212 failed to meet the minimum target pharmacokinetic concentration, making it difficult to dose adjust safely.
Financial ValuationThe negative pharmacokinetic data from RLYB212 is considered a major setback, as the FNAIT program represented the most significant component of the company's valuation.
Program DiscontinuationRallybio has announced the discontinuation of its RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia.
---
Options Prices
Currently, No data available
---
Ownership Overview
23.17%
Insiders
3.07% Mutual Funds
5.50% Other Institutional Investors
65.95% Public Companies and
Individual Investors
RLYB FAQ
What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $0.22 and its highest was $2.00 in the past 12 months.
What is Rallybio’s market cap?
Rallybio’s market cap is $13.19M.
When is Rallybio’s upcoming earnings report date?
Rallybio’s upcoming earnings report date is May 13, 2025 which is in 6 days.
How were Rallybio’s earnings last quarter?
Rallybio released its earnings results on Mar 13, 2025. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.038.
Is Rallybio overvalued?
According to Wall Street analysts Rallybio’s price is currently Undervalued.
Does Rallybio pay dividends?
Rallybio does not currently pay dividends.
What is Rallybio’s EPS estimate?
Rallybio’s EPS estimate is -0.26.
How many shares outstanding does Rallybio have?
Rallybio has 41,612,038 shares outstanding.
What happened to Rallybio’s price movement after its last earnings report?
Rallybio reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Rallybio?
Currently, no hedge funds are holding shares in RLYB
---
Rallybio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.00 (2087.50% Upside)
$7.00 (2087.50% Upside)
Blogger Sentiment
Bearish
RLYB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 21.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.67%
12-Months-Change
Fundamentals
Return on Equity
-68.85%
Trailing 12-Months
Asset Growth
-41.09%
Trailing 12-Months
Company Description
Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
---
RLYB Stock 12 Month Forecast
Average Price Target
$7.00
▲(2087.50% Upside)
Technical Analysis
Minerva Neurosciences
―
Moleculin Biotech
―
Marker Therapeutics
―
Addex Therapeutics
―
SeaStar Medical Holding
―
---